Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totaling 139 shares, a growth of 256.4% from the August 15th total of 39 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 18 shares, the short-interest ratio is currently 7.7 days.
Basilea Pharmaceutica Stock Performance
Shares of OTCMKTS BPMUF opened at $77.40 on Friday. The company has a quick ratio of 4.68, a current ratio of 5.11 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $67.65 and a 200 day moving average of $67.51. Basilea Pharmaceutica has a 12-month low of $59.29 and a 12-month high of $77.40.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
See Also
- Five stocks we like better than Basilea Pharmaceutica
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
